Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
12.80
+0.37 (2.98%)
At close: Nov 14, 2025, 4:00 PM EST
12.80
0.00 (0.00%)
After-hours: Nov 14, 2025, 4:20 PM EST
Nurix Therapeutics Revenue
Nurix Therapeutics had revenue of $7.89M in the quarter ending August 31, 2025, a decrease of -37.29%. This brings the company's revenue in the last twelve months to $83.69M, up 48.32% year-over-year. In the fiscal year ending November 30, 2024, Nurix Therapeutics had annual revenue of $54.55M, down -29.15%.
Revenue (ttm)
$83.69M
Revenue Growth
+48.32%
P/S Ratio
12.25
Revenue / Employee
$292,612
Employees
286
Market Cap
1.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2024 | 54.55M | -22.44M | -29.15% |
| Nov 30, 2023 | 76.99M | 38.36M | 99.31% |
| Nov 30, 2022 | 38.63M | 8.88M | 29.84% |
| Nov 30, 2021 | 29.75M | 11.93M | 66.95% |
| Nov 30, 2020 | 17.82M | -13.30M | -42.73% |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NRIX News
- 4 days ago - Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors - GlobeNewsWire
- 7 days ago - Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling - GlobeNewsWire
- 11 days ago - Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 15 days ago - Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock - GlobeNewsWire
- 23 days ago - Nurix Therapeutics, Inc. (NRIX) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs Transcript - Seeking Alpha
- 23 days ago - Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock - GlobeNewsWire
- 23 days ago - Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia - GlobeNewsWire